President and Chief Executive Officer
Kevin was a member of the group that developed the business plan and State Grant proposal which resulted in the creation of CID4. Prior to joining CID4, Kevin was Managing Director of Act Three Consulting, LLC. Act Three was formed in July 2007 to provide consulting services to management teams and their advisors during times of dramatic change. Prior to founding Act Three, Kevin spent nine years as President of Gambro, Inc., the US holding company for the publicly-traded, Swedish-based Gambro Group, until its acquisition by private equity investors in 2006. The US operations of Gambro included the manufacture and distribution of cardiovascular (CV), blood separation and renal dialysis products and the operation of US and international kidney dialysis centers. Before joining Gambro, Kevin was an audit partner in the Denver and New York offices of Ernst & Young, specializing in entrepreneurial services and led the formation of E&Y’s Denver Life Sciences Practice.
Richard C. Duke, Ph.D.
Founder and Chief Scientific Officer
Dr. Duke is a biotechnology executive, inventor, biomedical researcher and serial entrepreneur with fifteen years of experience in building, financing, and managing start-up biotechnology companies based on inventions made in Colorado’s non-profit research institutions. He is currently Co-scientific Founder, President and CEO of ApopLogic Pharmaceuticals. Dr. Duke is a Co-scientific Founder and former CEO, President and Director of GlobeImmune, Inc. and was involved in the formation of Sierra Neuropharmaceuticals where he was an initial Director. These Colorado-based companies have raised more than $150 million in financing and have multiple products in phase 1 and 2 human clinical trials. In addition to his entrepreneurial activities, Dr. Duke has over twenty-five years of experience in cutting-edge biomedical research and is a tenured faculty member in the Departments of Medicine (Medical Oncology) and Immunology at the University of Colorado Denver. Dr. Duke has provided independent 3rd-party research analysis in the life sciences sector to Janus Capital and to venture capital firms.